Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that on 17 January 2018 the European Patent Office granted a further European patent EP 1857547B to Silence.
The allowed claims of European patent EP 1857547B will provide Silence with further protection for its innovative chemical modification technology in Europe. Silence seeks to protect the value of its portfolio and investment, where necessary using all the legal means at its disposal.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics Plc, commented: “These newly granted claims add further value to our intellectual property portfolio, and strengthen our patent position in Europe.”
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
